comprehensive -WSS

comprehensive

author：fashion 2025-09-30 18:20:32 - browse：94

There’s a specter haunting Wall Street.

It started in biotech, where companies making drugs for the obesity-related liver disease NASH saw their valuations crash on the assumption that GLP-1 weight loss treatments would cut them out of the market. Then the Ozempic panic came for dialysis firms, whose stocks fell about 20% in a single day on the news that Novo Nordisk’s medicine had delayed the progression of kidney disease in a study enrolling people with type 2 diabetes.

Now analysts from every sector are cranking out research notes on the disparate, dramatic, and often debatable implications of GLP-1 drugs’ growing popularity, said Jared Holz, a health care specialist at Mizuho Securities. Buy Bumble, sell McDonald’s. Short Pepsi, go long Louis Vuitton. Put your money in sectors that cater to a svelte and sated brand of consumer, and get out of the ones that rely on excess and compulsion.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Synthetic human embryos? Researchers say term is overblown

WSS

Prince Harry seeks over $550,000 in phone hacking lawsuit against British tabloid publisher

People with substance use disorder deserve online privacy

What Wagner Group's armed rebellion could mean for Russia's endgame in Ukraine

Patients, doctors press FTC to beef up hospital merger scrutiny

Anger, defiance, fear over Supreme Court decision to block student loan forgiveness

Assistant physicians can help address the primary care shortage

explore

comprehensive

Wikipedia

Affirmative action in medical school literally saved lives

Belarusian journalist sentenced to 4 years in prison as crackdown continues

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Midwives could help bridge maternal health disparities in the U.S.

Heart attack and stroke risk calculators need revising

Illumina to lay off 10% of research and development team

Novavax promises a turnaround & Lilly roils the obesity market

Biden slams SCOTUS affirmative action decision: 'Discrimination still exists in America'

ChatGPT in medicine: STAT answers readers' burning questions

Ukrainian soldiers say they owe lives to US

hotspot

PBMs drew scrutiny in House hearing — and so did pharma

Why do we get seasonal allergies?

FDA weighs limits of animal data in assessing artificial wombs

The struggle to figure out which patients 'deserve' Wegovy

PBMs drew scrutiny in House hearing — and so did pharma

The sun may be out, but guns are not. A lawsuit challenges a new gun ban on Hawaii beaches

focus

focus

focus

focus